(Q40423639)

20 September 2017

title

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro (English)

1 reference

20 September 2017

1 reference

H G Jørgensen

1

1 reference

20 September 2017

E K Allan

2

1 reference

20 September 2017

S M Graham

3

1 reference

20 September 2017

J L Godden

4

1 reference

20 September 2017

L Richmond

5

1 reference

20 September 2017

M A Elliott

6

1 reference

20 September 2017

J C Mountford

7

1 reference

20 September 2017

C J Eaves

8

1 reference

20 September 2017

T L Holyoake

9

1 reference

20 September 2017

language of work or name

1 reference

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

19

1 reference

20 September 2017

issue

7

1 reference

20 September 2017

page(s)

1184-1191

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Imatinib mesylate in the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

High-resolution cell division tracking demonstrates the FLt3-ligand-dependence of human marrow CD34+CD38- cell production in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Functional consequence of MDR1 expression on imatinib intracellular concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403785

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403785

1 reference

Dimensions Publication ID

20 September 2017

1028517345

0 references

1 reference